COVID-19 rebound after oral treatment in a nursing home facility: A case series

Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2–8 days after completing the treatment cour...

Descripción completa

Detalles Bibliográficos
Autores principales: Betrosian, Alex P., Christou, Stavros M., Kalathaki, Stavroula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of Tsinghua University Press. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664743/
https://www.ncbi.nlm.nih.gov/pubmed/38013912
http://dx.doi.org/10.1016/j.imj.2022.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664743/
https://www.ncbi.nlm.nih.gov/pubmed/38013912
http://dx.doi.org/10.1016/j.imj.2022.10.003

Ejemplares similares